Fisher & Paykel Healthcare Corporation Limited
ロング
更新済

$FPH:ASX - FISHER & PAYKEL HEALTHCARE - Entry on pullback?

342
Fisher and Paykel have been having a great run so far this year up around 60% since the start of the year and not much sign of slowing down. The RSI is WAY overextended so I'm hoping that there might be a bit of a pullback / consolidation period allowing us to buy at better value before it continues so I have set an alert for when the RSI gets back to under 70 and see what happens then. Could be worth a watch.

Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The Company's segments include New Zealand, which includes all activities controlled by entities or employees based in New Zealand; North America, which includes all activities controlled by entities or employees based in the United States and Canada; Europe, which includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden, Turkey and Russia, and Asia-Pacific, which includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan and Hong Kong. Its products include respiratory humidifiers, single-use and reusable chambers and breathing circuits, infant resuscitators, infant warmers and accessories. In addition, the Company offers hardware and consumables.
ノート
Nice continuation of trend. RSI pointing up so hopefully will continue its run after minor pullback.

スナップショット
ノート
Bit more info on its bounce.

スナップショット
ノート
Slow and steady - up 16% from when first spotted.

スナップショット
ノート
Up over $25 and continues to shrug off the market volatility.

スナップショット
ノート
Got a bit wobbly - would have needed a 20% trail to stay in. Back pushing the $35 mark again.

スナップショット
ノート
Feeling a bit flat across the top so will tighten trail.

スナップショット

免責事項

この情報および投稿は、TradingViewが提供または推奨する金融、投資、トレード、その他のアドバイスや推奨を意図するものではなく、それらを構成するものでもありません。詳細は利用規約をご覧ください。